These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35209781)

  • 41. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
    De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
    J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. JAK inhibitors for asthma.
    Georas SN; Donohue P; Connolly M; Wechsler ME
    J Allergy Clin Immunol; 2021 Oct; 148(4):953-963. PubMed ID: 34625142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis.
    Palominos PE; Lineburger IB; Xavier RM
    Expert Opin Emerg Drugs; 2021 Sep; 26(3):303-321. PubMed ID: 34365877
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum.
    El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
    Joint Bone Spine; 2020 Mar; 87(2):119-129. PubMed ID: 31521793
    [TBL] [Abstract][Full Text] [Related]  

  • 45. JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function.
    Adam S; Simon N; Steffen U; Andes FT; Scholtysek C; Müller DIH; Weidner D; Andreev D; Kleyer A; Culemann S; Hahn M; Schett G; Krönke G; Frey S; Hueber AJ
    Sci Transl Med; 2020 Feb; 12(530):. PubMed ID: 32051226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective JAK inhibitors in development for rheumatoid arthritis.
    Norman P
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1067-77. PubMed ID: 24818516
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
    Alunno A; Padjen I; Fanouriakis A; Boumpas DT
    Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis.
    Kim H
    Expert Rev Clin Immunol; 2024 Jun; 20(6):589-602. PubMed ID: 38299575
    [TBL] [Abstract][Full Text] [Related]  

  • 49. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
    Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
    BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
    [TBL] [Abstract][Full Text] [Related]  

  • 50. JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis.
    Kahn JS; Deverapalli SC; Rosmarin DM
    Int J Dermatol; 2018 Aug; 57(8):1007-1014. PubMed ID: 29873082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors.
    Pin A; Tesser A; Pastore S; Moressa V; Valencic E; Arbo A; Maestro A; Tommasini A; Taddio A
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33092242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus.
    Nakayamada S; Tanaka Y
    Expert Rev Clin Immunol; 2022 Mar; 18(3):245-252. PubMed ID: 35138987
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats.
    Calbet M; Ramis I; Calama E; Carreño C; Paris S; Maldonado M; Orellana A; Calaf E; Pauta M; De Alba J; Bach J; Miralpeix M
    J Pharmacol Exp Ther; 2019 Aug; 370(2):137-147. PubMed ID: 31085698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
    Jegatheeswaran J; Turk M; Pope JE
    Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
    Migita K; Izumi Y; Torigoshi T; Satomura K; Izumi M; Nishino Y; Jiuchi Y; Nakamura M; Kozuru H; Nonaka F; Eguchi K; Kawakami A; Motokawa S
    Clin Exp Immunol; 2013 Dec; 174(3):356-63. PubMed ID: 23968543
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
    Garcia-Melendo C; Cubiró X; Puig L
    Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
    Kim HO
    Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
    [TBL] [Abstract][Full Text] [Related]  

  • 58. JAK selectivity: more precision less troubles.
    Roda G; Dal Buono A; Argollo M; Danese S
    Expert Rev Gastroenterol Hepatol; 2020 Sep; 14(9):789-796. PubMed ID: 32520647
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
    Orsolini G; Bertoldi I; Rossini M
    Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [JAK Inhibitors in Rheumatology].
    Witte T
    Dtsch Med Wochenschr; 2019 Jun; 144(11):748-752. PubMed ID: 31163474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.